Forget This Biotech Stock’s Rally Signals Fresh Jump
NovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
Determine which funds deliver the best annual risk-adjusted returns and how they stack up. Compare contenders to pick winners.
28,456 articlesNovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
In a briefing, the legal chief puts clarity on the bill's fate, pointing to sub-50% odds this Senate session due to s...
ADA neared a multi-year trough as markets digested a broad crypto selloff. Analysts warn gains may come, but a cardan...
As retirement checks begin, a rising share of households worry about debts that survive into retirement. The IRS can ...
A growing longevity gap is changing the lifetime value of Social Security, shifting advantage away from some low-wage...
As XRP weathered a months-long retreat, new regulatory wins, steady ETF inflows, and surging on-chain activity are fu...
Disney faces a growing disney narrative problem wall as Wall Street questions leadership, strategy, and long-term pro...
A shift in AI hardware could redefine winners and losers in tech investing. Here’s how ASICs may outpace GPUs and whi...
Alphabet reportedly priced a rare 100-year bond to back AI and data-center expansion, a move that stirs debate on lon...
A broad sell-off hit four key quantum names after a sharp Monday rally, with profit-taking and sentiment shifts weigh...
Ray Dalio’s Suez analogy returns to the headlines as markets weigh the U.S. risk of a reserve-currency shift and a we...
When a company's CEO sells 31,000 shares worth roughly $1.41 million, it sparks questions for investors. This guide e...